Three oncology perspectives have analyzed a cancer case: Tumor Board: Guidelines: The diagnosis of prostatic...
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Question asked:
Three oncology perspectives have analyzed a cancer case: Tumor Board: Guidelines: The diagnosis of prostatic adenocarcinoma is definitively correct based on surgical pathology, but the characterization as 'unknown' stage/grade is incomplete and misleading. This patient has well-documented pT3b-pT4a pN1 disease (Stage IIIC/IVA), Gleason 4+5=9 (Grade Group 5), with seminal vesicle invasion, bladder neck invasion, and nodal metastases—representing high-risk, locally advanced disease with biochemical recurrence. Recommendation: The diagnosis should be updated to: 'Prostatic adenocarcinoma, acinar type, Gleason 4+5=9 (Grade Group 5), pT3b-4a pN1 M1a (AJCC 8th edition Stage IVA), with biochemical recurrence and oligometastatic nodal disease, AR-overexpressed, MSI-stable.' Per NCCN Guidelines, confirm current PSA, testosterone level (appears castrate at 28 ng/dL per recent labs), and restaging imaging (PSMA PET or conventional CT/bone scan) to define extent of recurrent disease and guide systemic therapy intensification versus metastasis-directed therapy. Tumor Board: Cutting Edge: The diagnosis of prostatic adenocarcinoma is definitively correct based on surgical pathology, but 'unknown' stage is incomplete and misleading. Russell has pathologically-confirmed pT3b-pT4a N1 disease (Stage IIIC/IVA) with Gleason 4+5=9, extraprostatic extension, seminal vesicle invasion, bladder neck invasion, and nodal metastases. The current biochemical recurrence (PSA 0.4-0.56, positive ctDNA August 2025) represents oligometastatic progression requiring restaging. Recommendation: Immediate restaging with PSMA PET/CT (Pylarify or Illuccix) and consideration of image-guided biopsy of PSMA-avid periaortic nodes to confirm oligometastatic recurrence versus treatment effect. Explore clinical trials targeting KMT2D-mutant, AR-overexpressed disease (NCT04471974 for EZH2 inhibitors in KMT2D-altered cancers; NCT03385655 for AR-targeted radioligand therapy). Given intermediate PSMA expression and nodal-only disease, metastasis-directed therapy (SBRT to oligometastatic nodes) plus intensified systemic therapy (ADT + novel AR inhibitor + potential PARP inhibitor given DNA repair pathway involvement) should be discussed. Repeat ctDNA monitoring every 3 months as molecular surveillance tool. Tumor Board: Whole Person: The diagnosis of prostatic adenocarcinoma is definitively correct based on surgical pathology showing Gleason 4+5=9 (Grade Group 5) disease with extraprostatic extension, seminal vesicle invasion, bladder neck invasion, and lymph node metastasis (pT3b-4a N1). However, the staging is incomplete - this is NOT 'unknown stage' but rather Stage IV (AJCC 8th edition) high-risk metastatic disease. The current challenge is determining disease activity status given conflicting signals: detectable ctDNA in August 2025 (0.14 MTM/mL) versus undetectable in November 2025, with persistently low but detectable PSA (0.4-0.56 ng/mL) and castrate testosterone levels (28 ng/dL). Recommendation: The diagnosis should be updated to 'Prostatic adenocarcinoma, Gleason 4+5=9, Stage IV (pT3b-4a N1 M0), status post-radical prostatectomy with biochemical persistence/recurrence, currently on androgen deprivation therapy with oligometastatic nodal disease.' Immediate needs: (1) Repeat PSMA-PET to correlate with ctDNA fluctuation and assess for oligoprogression amenable to metastasis-directed therapy, (2) Serial ctDNA monitoring every 3 months to establish trend given discordant August/November results, (3) Confirm castration status and consider intensified systemic therapy (abiraterone/enzalutamide + ADT per NCCN guidelines for high-risk biochemical recurrence) versus observation if truly MRD-negative, and (4) Multidisciplinary tumor board review to determine if salvage radiation to prostate bed + pelvic nodes is indicated given N1 disease and detectable PSA. Synthesize these perspectives. Respond in this exact JSON format: { "synthesis": "A 2-3 sentence synthesis of the key takeaways for the patient", "consensus": ["Point where all three agree", "Another point of agreement"], "divergence": ["Point where they disagree", "Another area of disagreement"] } Focus on actionable insights for the patient's next doctor conversation.
{
"synthesis": "All three oncologists agree your diagnosis needs updating from 'unknown stage' to Stage IV prostate cancer (Gleason 4+5=9, the highest grade) with lymph node involvement, and that you need immediate restaging with a PSMA PET scan to see where the cancer is now. The key question they're wrestling with is whether your mixed signals—detectable ctDNA in August but undetectable in November, plus low but persistent PSA—mean you need treatment intensification now or can continue careful monitoring.",
"consensus": [
"Your diagnosis should be updated to Stage IV (pT3b-4a N1) Gleason 4+5=9 prostate cancer with biochemical recurrence—not 'unknown stage'",
"You need immediate restaging with PSMA PET/CT imaging to locate any active disease and guide treatment decisions",
"Your conflicting test results (fluctuating ctDNA, low but detectable PSA at 0.4-0.56) require serial monitoring every 3 months to establish a clear trend",
"Confirm your testosterone remains at castrate levels (it was 28 ng/dL, which is good) and verify current PSA"
],
"divergence": [
"Guidelines perspective recommends confirming disease extent then following standard NCCN pathways (intensified hormone therapy), while Cutting Edge suggests exploring clinical trials targeting your specific mutations (KMT2D) and considering metastasis-directed radiation to visible spots",
"Whole Person perspective emphasizes the possibility of observation if November's undetectable ctDNA represents true minimal residual disease, while the other two lean toward treatment intensification given the August ctDNA detection and persistent PSA",
"Cutting Edge uniquely recommends biopsy of any PSMA-avid lymph nodes to confirm active cancer versus scar tissue, which the others don't mention"
]
}
This is general information.
Upload your records for guidance specific to YOUR diagnosis — personalized to your biomarkers, stage, and treatment history.
Related Services
Services that may help with treatment for cancer patients
Get guidance specific to your case
This answer covers general information. For guidance based on YOUR records, biomarkers, and treatment history:
Related Questions
Er+ oligomet breast cancer. Have been 5aking ribocyclib for 14 months. Because of my low neutrophils the dose was...
I appreciate you sharing these details about your treatment journey. Let me help you understand what's happening and what questions to bring to your o
What signs of progression should I watch for
Based on NCCN Guidelines for Myeloproliferative Neoplasms, here are the key warning signs you should monitor and report to your oncologist: Blood Co
What questions should I ask my oncologist at my next appointment
I'd love to help you prepare for your appointment! To give you the most relevant questions, it would help to know a bit more about your situation: 1.
What are treatment options for KRAS G12A and PIK3CA mutations in colorectal cancer
Thank you for the follow-up. I want to address something important that emerged from your medical profile: Your actual diagnosis is a fibroblastic/my
What are treatment options for KRAS G12A and PIK3CA mutations in colorectal cancer
I appreciate your question about these specific mutations. However, I want to first clarify something important about your medical profile: Your Situ